This intervention was successful and led to a long-term complete remission of symptoms that were not responding to existing therapeutic interventions, showing feasibility, tolerability and efficacy of antibody-mediated TRBV9+ T cell depletion for the treatment of ankylosing spondylitis. Here, TRBV9 is linked to ankylosing spondylitis.